3rd International Conference on
Deficiency of Adenosine Deaminase 2
We look forward to welcoming you and fellow clinicians and researchers dedicated to finding a cure for this disease. While COVID-19 restrictions prevent our in-person gathering, we are pleased to open access via a virtual conference experience to our global community of hundreds of clinicians and researchers who are dedicated to this collaborative approach. Together, we will continue our work to improve the lives of DADA2 patients around the world.
Ready for the Conference?
We are live starting at 7:00 a.m. eastern, November 17, 18 & 19
If you need to register, click below.
What will we accomplish together?
The DADA2 Foundation is pursuing a model for the fastest path to curing rare diseases
- with DADA2 as our top focus. This year's theme is: Driving Toward Consensus.
From discovery to diagnosis to treatment, our goal is to change both the day-to-day experiences and the future prognosis for patients and families as they live their best quality of life with this rare disease.
Dr. Dan Kastner, Scientific Director of the National Human Genome Research Institute (NHGRI) at the NIH, will again moderate the conference. Highlights of the scientific meeting’s agenda include:
- Presentations from global researchers and clinicians
- Discussions among researchers with alternate viewpoints on critical issues
- Updates from global cohorts on unique patient experiences and research findings
While patients are an absolutely critical aspect of our network, we will bring them together in 2021 in a reimagined virtual, in-person, or hybrid format, depending on the development of safe travel guidelines under COVID.
Goals of the Conference
Scientific Discovery & Progress
Discussion & Relationships
Growth & Collaboration
Who Should Attend?
Researchers currently studying DADA2 or those interested in studying the function of ADA2 in patients.
Clinicians treating DADA2 patients throughout the globe.
Aligned scientists, Biotech, Pharma and other medical professionals interested in learning more about DADA2 and our unique rare disease community.